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A B S T R A C T
Background
It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the
process of light absorption.
Objectives
The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of age-
related macular degeneration (AMD).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2007, Issue 3); MEDLINE
(1966 to August 2007); EMBASE (1980 to August 2007); NRR (2007, Issue 3); AMED (1985 to January 2006); PubMed (24 January
2006 covering last 60 days) and SIGLE (1980 to March 2005), reference lists of identified reports and the Science Citation Index. We
contacted investigators and experts in the field for details of unpublished studies.
Selection criteria
We included randomised trials comparing antioxidant vitamin or mineral supplementation (alone or in combination) to a control
intervention in people with AMD.
Data collection and analysis
The author extracted data and assessed trial quality. Where appropriate, data were pooled using a random-effects model unless three or
fewer trials were available in which case a fixed-effects model was used.
Main results
Nine trials were included in this review. The majority of people were randomised in one trial (AREDS in the USA) that found a
beneficial effect of antioxidant (beta-carotene, vitamin C and vitamin E) and zinc supplementation on progression to advanced AMD
(adjusted odds ratio 0.68, 99% confidence interval 0.49 to 0.93). People taking supplements were less likely to lose 15 or more letters
of visual acuity (adjusted odds ratio 0.77, 99% confidence interval 0.58 to 1.03). Hospitalisation for genito-urinary problems was
more common in people taking zinc and yellowing of skin was more common in people taking antioxidants. The other trials were, in
general, small and the results were inconsistent.
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Authors’ conclusions
The evidence as to the effectiveness of antioxidant vitamin and mineral supplementation in halting the progression of AMD comes
mainly from one large trial in the USA. The generalisability of these findings to other populations with different nutritional status
is not known. Further large, well-conducted randomised controlled trials in other populations are required. Long-term harm from
supplementation cannot be ruled out. Beta-carotene has been found to increase the risk of lung cancer in smokers; vitamin E has been
associated with an increased risk of heart failure in people with vascular disease or diabetes.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamins and mineral supplements to slow down the progression of age-related macular degeneration
Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can
deteriorate with age and some people get lesions that can lead to loss of central vision. It has been suggested that progression of the
disease may be slowed down in people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium
and zinc). The author identified nine randomised controlled trials; four trials based in the USA, four in Australia, Austria, Switzerland
and the UK and one in China. The review of trials found that supplementation with antioxidants and zinc may be of modest benefit in
people with AMD. Long-term harm from these supplements cannot be ruled out. Large well-conducted trials in a range of populations
and with different nutritional status are required.
B A C K G R O U N D
Introduction
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the disease
lipid material accumulates in deposits underneath the retinal pig-
ment epithelium. These deposits are known as drusen and can be
seen as pale yellow spots on the retina. The pigment of the retinal
pigment epitheliummay become disturbedwith areas of hyperpig-
mentation and hypopigmentation. In the later stages of the disease
the retinal pigment epithelium may atrophy completely. This loss
can occur in small focal areas or can be widespread (geographic).
In some cases new blood vessels grow under the retinal pigment
epithelium and occasionally into the subretinal space (exudative or
neovascular AMD). Haemorrhage can occur which often results
in increased scarring of the retina.
Presentation and epidemiology
The early stages of the disease are in general asymptomatic. In
the later stages there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision. Population-based studies suggest that in people 75 years
and older, approximately 30% have early signs of the disease and
7% have late-stage disease (Klein 1992). It is the most common
cause of blindness and visual impairment in industrialised coun-
tries. In the UK, for example, over 30,000 people annually are
registered as blind or partially sighted, half of whom have lost their
vision due to macular degeneration (Evans 1996).
Treatment options
Currently there is no treatment that can restore vision in AMD.
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by limiting the damaging effects of free radicals pro-
duced in the process of light absorption (for a review see Christen
1996). Antioxidant vitamin and mineral supplements are increas-
ingly being marketed for use in age-related eye disease, including
AMD.
O B J E C T I V E S
The objective of this review was to assess the effects of antioxidant
vitamin or mineral supplementation, alone or in combination, on
the progression of AMD.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
This review included randomised controlled trials.
Types of participants
Participants in the trials were people with AMD in one or both
eyes.
Types of interventions
We included trials in which antioxidant vitamin or mineral sup-
plementation, alone or in combination, was compared to placebo
or no intervention. Antioxidants were defined as any vitamin or
mineral which is known to have antioxidant properties in vivo or
which is known to be an important component of an antioxidant
enzyme present in the retina. The following were considered: vi-
tamin C, vitamin E, carotenoids, selenium and zinc.
Types of outcome measures
Primary outcomes
The primary outcome for this review was vision.
As one of the consequences of AMD is a progressive loss of vision
the preferred outcomewas dichotomous (loss of three ormore lines
of visual acuity) which, if measured on a logMAR chart, reflects a
doubling of the visual angle. This is a meaningful clinical change
for patients. However, some studies report vision as a continuous
measure so I also looked at the mean difference. If there were
studies that used different ways of measuring vision (for example,
some may report vision at the end of the study, some may report
change) I calculated a standardised mean difference. Snellen values
were converted to logMAR to ensure that there was consistency in
the direction of effect (higher Snellen values reflect better vision,
higher logMAR values reflect poorer vision).
Secondary outcomes
Secondary outcomes included progression of the disease. There
are several ways of measuring this. I decided to use progression as
defined by the study investigators as the outcome. This was usually
reported as a dichotomous outcome.
Other outcomes included contrast sensitivity, which is measured
on a continuous scale, analysed as a mean difference or standard-
ised mean difference if different measurement scales were used.
Quality of life was also to be assessed if data were available.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) in The Cochrane Library, MEDLINE, EM-
BASE, National Research Register (NRR), PubMed, Allied &
Complementary Medicine (AMED), SIGLE. The searches in The
Cochrane Library, MEDLINE, EMBASE and NRR were last up-
dated on 2 August 2007. There were no language or date restric-
tions in the searches.
See: Appendices for details of search strategies for each database.
All possible AMD trials were examined for trials of vitamin and
mineral supplements.
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials. The Science Citation Index was used to find
studies that cite the identified trials. We contacted investigators of
included studies to identify additional published and unpublished
studies.
Data collection and analysis
Selection of trials
The author assessed the titles and abstracts of all reports of trials
identified by the electronic searching. The full texts of possibly
relevant trials were obtained. Relevant studies were selected ac-
cording to the definitions in the ’Criteria for considering studies
for this review’.
Assessment of methodological quality
The author assessed trial quality according to methods set out in
Section 6 of theCochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2006). Five parameters were considered: alloca-
tion concealment, method of allocation to treatment, documenta-
tion of exclusions, masking of outcome assessment and complete-
ness of follow up.
Each parameter of trial quality was graded: A, low risk of bias;
B moderate risk of bias; or C high risk of bias. The author was
not masked to the report authors or the trial results. The a priori
criterion for exclusion was that trials scoring C on allocation con-
cealment (that is, where allocation was not concealed properly)
were excluded.
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Data collection
The author extracted data using a standardised form developed by
the Cochrane Eyes and Vision Group. These data were sent for
verification to the trial investigators of all studies included in the
review.
Analysis strategy
Previous versions of this review did not include statistical analyses
because only a small number of trials were identified and variable
methods of collecting and presenting outcome data were used.
More trials in this area have become available and new develop-
ments in statistical software and Cochrane guidelines mean that
the analysis section was substantially revised for later versions of
the review.
The following plan was set out (and reviewed by the statistical
editorial team) in September 2005, before re-doing the analyses.
It should be noted that this plan was developed with knowledge
of the trials and the results included in previous versions of this
review. However, every effort has been taken to base judgements
as to the analysis on methodological grounds without reference to
the results of the individual trials.
Comparisons
The overall objective of the review was to assess the impact of
antioxidant vitamin and mineral supplements on the progression
of AMD. Trials in this area fall into two broad categories: those
evaluating a single vitamin or mineral (for example, vitamin E or
zinc) and those investigating a broad spectrum formulation (for
example, Ocuguard). The following comparisons were considered
in this review.
(1) Broad-spectrum formulation versus placebo. Within this cat-
egory fall all the broad-spectrum formulations which include one
or more antioxidant vitamins or minerals.
(2) Single-component formulations versus placebo.Currently only
vitaminE, zinc and lutein have been studied as single formulations,
however, it is likely that in future other trials will be published
which investigate individual components.
(3) All trials of broad-spectrum or single component studies to-
gether.
The traditional study design method in this area is parallel group
randomised controlled trials. Cluster randomised trials are unlikely
but would still be considered. Cross-over studies would not be
appropriate in this area because of the uncertain and complex
natural history of AMD. If such studies are reported the first phase
only would be used.
Some studies report findings on right eyes and left eyes separately.
As there is no hypothesis that the effect of antioxidant supplements
should differ according to eye, I have made the a priori decision
to consider right eyes only.
Which measure of effect?
In general the risk ratio is to be preferred when the proportion of
the control group experiencing the event of interest is greater than
10%. However, in this particular case the main trial from which
over 80%of the informationon this topic is available reported odds
ratios and their confidence intervals only (derived from repeated
measures logistic regression). For this reason, I have analysed the
data using the generic inverse variancemethodwith themain effect
measure being the odds ratio. The standard error was calculated
from the confidence interval from each study. In discussion of the
results of the review, where possible, I have converted the pooled
odds ratio back to the risk ratio to ensure that any estimates of
effect are not exaggerated. The risk ratio was calculated using the
following formula: RR = OR/[(1-P0)+(P0xOR)] where P
0 is the
incidence of the outcome of interest in the control group.
How will the decision be made as to whether it is appropriate
to pool data?
I considered how similar the trials were and looked at the forest
plot to see whether the effect measures for the different studies
were in the same direction and of a similar order of effect. I then
examined the I2 value. A value of 50% or more was taken to
indicate considerable inconsistency of results such that a pooled
result may be inaccurate and should not be reported.
Which model will I use?
I used a random-effects model, unless there were three or fewer
trials in which case I used a fixed-effect model. I compared fixed
and random-effects models to see how robust the result was.
How will clinical and methodological diversity be addressed?
How will these be incorporated into the analysis strategy?
The main clinical diversity was with respect to the type of sup-
plement. This is incorporated into the analysis strategy by consid-
ering the formulations by type (see Comparisons 1 and 2). Again
with methodological diversity, the type of study design was fairly
standard and straightforward, however, the methodological qual-
ity of the studies was reported and used to interpret the results (see
below).
How will the quality of included studies be addressed in the
analysis section?
Currently there are not enough published studies to enable sensi-
tivity analysis. However, should enough studies become available
in the future, the proposal would be to repeat the analysis includ-
ing only high quality studies. All studies included in the review
were randomised controlled trials. The main quality attributes in
this area are: (i) whether or not the randomisation was properly
concealed, (ii) whether or not the participants were masked, (iii)
whether or not the outcome assessment was masked, and (iv) ex-
tent of follow up in the study groups. In practice, most studies
compare the supplements versus placebo and report that themask-
ing was adequate, that is that the tablets were similar etc. It is likely
that the main quality attributes that may differ between studies
will be allocation concealment and follow up.
Pre-specify characteristics of the studies that may be examined
as potential causes of heterogeneity
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Currently there are not enough studies to perform any sub-group
analyses and these are not proposed for this version of the review.
One characteristic that may be important is the type of AMD or
severity of AMD. Subgroup analyses on type or severity of AMD
may be considered in future.
How will missing data be handled?
It was proposed to do an available case analysis.
Currently only one study (Stur 1996) specifically excluded peo-
ple who experienced a neovascular event (one component of late
stage AMD) from the analyses. The published report did not give
enough information to include these people in the analyses.
If missing data should prove to be a problem in the constituent
studies, that is if followupwas less than 80% for trials contributing
more than 50% of the data for the analysis, I will do a sensitivity
analysis considering outcome in the people lost to follow up as
either ’all OK’ or ’all not OK’ to see the range within which the
true result might lie. However, currently this was not considered
to necessary as the largest trial in the area had follow up of nearly
98%.
Whether or how evidence of possible publication or reporting
biases will be sought
Currently there are not enough studies to examine this formally,
however, I reviewed the forest plots to see if there was any sign
that this might be happening i.e. whether smaller studies were
reporting larger effects.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The original electronic searches identified 577 reports of possi-
ble AMD trials of which five reports (four trials) were of antioxi-
dant interventions (AMDSG; Kaiser 1995; Newsome 1988; Stur
1996). These four trials met the inclusion criteria for this review.
Contact with a trial author identified an additional trial of zinc
supplementation that has been published in abstract form only
(Holz 1993).
In October 2001, the result of the Age-Related Eye Disease Study
(AREDS) was published. The reference list of this study report
identified that the Vitamin E, Cataract and Age-related Macu-
lopathy Study (VECAT) had been published in abstract form.
Searching the reference lists of trial reports located one further
possible relevant trial (Vannas 1958). This study was not included
in the reviewbecause therewas no evidence from the report that the
comparison groups (heparin, vitamin A and E, Hydergin therapy
and placebo) were randomly allocated or that the allocation was
concealed in any way. As the trial was conducted in 1958, no
further attempt was made to clarify this.
A trial of zinc supplementation (30 mg daily) of people with neo-
vascular AMD in one eye and drusen in the other (n = 170) has
been conducted and is as yet unpublished (France 1998). This
trial is listed as ’Awaiting assessment’ in this review.
Searches were first performed in August 1997 and repeated in Oc-
tober 1998, December 1999, September 2000, November 2001
and May 2005. Two further trials were identified: Veterans LAST
study and a trial published in Chinese which is currently awaiting
assessment (Wang 2004). The searches were updated in January
2006 and August 2007 but no new trials were identified.
Included studies
Below is a summary of the eight trials included in this review.
See ’Characteristics of included studies’ for detailed information
about the trials.
Types of participants
The average age of people participating in the trials was 70 years.
Slightly more women than men were recruited with the exception
of AMDSG and Veterans LAST study where predominantly men
were enrolled. In AREDS it was noted that people taking part in
the trial were relatively well-nourished compared to the general
population.
People taking part in the trials were identified by referral from
local ophthalmologists (Kaiser 1995; Newsome 1988), from peo-
ple attending Department of VeteransMedical Centers (AMDSG;
Veterans LAST study), from retinal specialty clinics and gen-
eral population volunteers (AREDS), from an eye outpatient
clinic (Stur 1996; Wang 2004) and from the general population
(VECAT).
The trials enrolled groups of people with AMD at different stages
of the disease: AMDSG and Veterans LAST study considered peo-
ple with early macular degeneration only; Newsome 1988 exam-
ined people with both early and late-stage disease; Stur 1996 en-
rolled only people with late-stage disease in one eye; Kaiser 1995
recruited only people with geographic AMD. In AREDS partic-
ipants had a range of disease from mild or borderline features to
advanced AMD which was defined as geographic atrophy involv-
ing the centre of the macula or features of choroidal neovasculari-
sation. Themajority of the participants in VECAT had no or mild
age-related maculopathy.
Types of intervention
Three trials compared zinc sulfate 200 mg daily versus placebo
(Holz 1993; Newsome 1988; Stur 1996). Two trials compared a
broad-spectrum antioxidant complex versus placebo (AMDSG -
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Ocuguard; Kaiser 1995 - Visaline). VECAT compared vitamin E
(500 international units (IU) daily) with placebo. In AREDS a 2x2
factorial design was used. Participants were randomised into four
groups: placebo, zinc alone (80 mg daily), antioxidants (vitamin
C 500 mg, vitamin E 400 IU and beta-carotene 15 mg) alone
and zinc plus antioxidants. In AREDS 67% of participants took
other multivitamin supplements to recommended daily allowance
levels (Centrum). The Veterans LAST study compared lutein 10
mg daily to lutein plus a broad-spectrum antioxidant (OcuPower).
The duration of supplementation in these trials ranged from six
months to seven years. The Chinese trial studied zinc oxide (80mg
daily), vitamin C (dose unknown) and vitamin E (dose unknown).
Types of outcome measures
All the trials used different outcome measures for visual function
and progression of disease. AMDSG and Veterans LAST study
measured vision using Snellen acuity and converted the score into
logMAR units. Newsome 1988 and AREDS used the visual acu-
ity chart developed as part of the Early Treatment of Diabetic
Retinopathy Study (ETDRS 1980). Stur 1996 and VECAT used
Bailey-Lovie Charts #4 and #5 (National Vision Research Insti-
tute, Australia). Some studies have presented vision as a contin-
uous outcome (AMDSG; Kaiser 1995; Stur 1996), others have
used a cut-off of loss of 10 (Newsome 1988) or 15 letters of acuity
(AREDS). A loss of 15 letters of acuity is equivalent to a loss of
three lines of vision read on the chart and is the same as experi-
encing a doubling of the visual angle.
In most studies disease progression was assessed by grading stereo-
scopic colour photographs of the retina. Stur 1996 used the Wis-
consin Age-Related Maculopathy Grading System (Klein 1991);
AMDSG used the grading system developed as part of the Chesa-
peake Bay Waterman Study (Bressler 1989); VECAT used the In-
ternational Grading System (ARMSG1995); AREDS adapted the
Wisconsin system. TheWisconsin, AREDS and International Sys-
tems are closely related; the latter was published after the two for-
mer systems were in use. All these grading systems involve classifi-
cation into categories according to the number and type of drusen,
pigmentary abnormalities and presence of geographic atrophy or
neovascularisation. In AMDSG and Stur 1996 these categories
were accorded a score which was analysed as a continuous mea-
sure. Newsome 1988 recorded the number of cases of increased
drusen, pigment abnormalities and atrophy. Kaiser 1995 did not
include any measures of progression of AMD.
AREDS reported data for three categories of participant: (i)mild or
borderline AMD features (n = 1063); (ii) AMD but not advanced
AMD (n = 1621) and (iii) advanced AMDor reduced visual acuity
due to AMD in one eye (n = 956). Advanced AMD was defined
as signs of geographic atrophy involving the centre of the macula
or signs of choroidal neovascularisation (defined as the presence
of fluid, blood or fibrovascular tissue under the retina or retinal
pigment epithelium).
The study followed up 90% of the cohort by the end of five years;
the mean follow-up time was 6.3 years. On the basis of having
missed the last two consecutive study visits, 2.4% were defined as
lost to follow up. In the borderline AMD group, 1.3% progressed
to advanced AMDby five years (15 AMD events); in the advanced
AMD category, 43% progressed to advanced AMD (in the other
eye) by five years and 18% progressed in the intermediate group.
At five year follow up 71% of participants were taking 75% or
more of their tablets.
The investigators found that individuals with outcomes such as
signs of advanced AMD and visual acuity loss of 15 or more letters
could recover later on. Approximately 8% of the identified cases
of advanced AMD, based on central grading of colour stereo pho-
tographs, apparently recovered as the AMD lesions were not seen
on subsequent yearly photographs. The report did not distinguish
between grading errors and verified disappearance of lesion. For
this reason they used repeated measures logistic regression which
counts each event but also allows for the fact that the event could
’recover’.
Outcomes were not clearly defined for the Chinese trials (Wang
2004).
Risk of bias in included studies
Most of the trials were small. The number of participants for
which data were analysed ranged from 20 to 151. In only one trial
(Stur 1996) was an a priori sample size estimate reported but the
trial was terminated early when follow up of the first 40 patients
showed no detectable trend. The more recent trials, AREDS and
VECAT, were larger at 3640 and 1204 participants respectively
and were based on prior sample size calculations. In the case of
VECAT, however, sample size was based on estimated prevalence
and incidence of cataract rather than age-related maculopathy. In
addition,most of the 1204 participants did not have signs of AMD
at the beginning of the study and were, therefore, are also included
in the related Cochrane review on prevention of AMD (Evans
2008).
Inmost trials randomisation appeared to have been executed prop-
erly, that is, an unpredictable sequence of treatment allocation was
concealed adequately from people recruiting participants into the
trial. As Holz 1993 has only been published in abstract form to
date the details of randomisation were not clear. In AMDSGmore
people in the placebo group withdrew (six) compared to the treat-
ment group (one). The description of the tablets cannot exclude
the possibility that there were detectable differences between treat-
ment and placebo that may mean that some participants in the
study were unmasked. In AREDS four people were documented
as being unmasked to study group. More people in the antiox-
idant group (8.3%) reported changes in skin colour (yellowing)
than in the placebo group (6.0%, P < 0.01) and more people in
the zinc groups reported difficulty swallowing the study tablets
(17.8% versus 15.3%, P = 0.04). However, there was little evi-
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dence of unmasking when at the end of the study participants
were asked to guess their treatment assignment. The percentages
of participants who guessed correctly, by treatment assignment,
were: placebo 17%, antioxidants alone 16%; zinc alone 18%; and
antioxidants plus zinc 16%.
In the Veterans LAST study the tablets were apparently identical
in appearance but it was not clear whether taste or systemic effects
differed between the different groups.
In Stur 1996 analysis of the main outcome measures (visual func-
tion and progression of disease) was not done on a strictly inten-
tion-to-treat basis as anyone experiencing the endpoint of late-
stage AMD (neovascularisation) was withdrawn from the study.
Contact with the trial investigator revealed that all of these par-
ticipants ended up with visual acuity of 20/200 or less and that
these participants were excluded because the investigators wished
to detect functional changes caused by degeneration of the retinal
pigment epithelium and the sensory retina and not vision losses
caused by choroidal neovascularisation.
Therewas not enough information available for the trial conducted
in China (Wang 2004) to assess study quality (see ’Characteristics
of included studies’ table).
Effects of interventions
Table 1 provides more information on the outcomes and follow-
up times relating to the data included in these analyses.
Comparison 1: multivitamin supplement versus
placebo
These analyses were restricted to trials ofmultivitamin andmineral
supplements: AREDS (vitamins C, E, beta-carotene and zinc),
AMDSG (Ocuguard), Kaiser 1995 (Visaline) and Veterans LAST
study (Ocupower). See ’Characteristics of included studies’ for
details of vitamins and minerals included in Ocuguard, Visaline
and Ocupower.
Outcome 1 distance visual acuity: loss of three or more lines
Only AREDS reported visual acuity data in a dichotomous format.
People who received antioxidant vitamins plus zinc were less likely
to lose 15 or more letters of visual acuity. The odds ratio (OR)
adjusted age,sex, race, AMD category and baseline smoking status
was 0.77, 95% CI 0.62 to 0.96.
Outcome 2 distance visual acuity: mean
Trials reporting visual acuity in continuous format were smaller
and had shorter treatment and follow-up durations (6 months
to 18 months) (AMDSG; Kaiser 1995; Veterans LAST study). A
total of 69 people were randomised to treatment and 62 to placebo
in pooled analyses of all three trials. The results of these trials were
consistent I² = 0. Little effect of treatment on visual acuity was seen
from these analyses. The pooled standardised mean difference was
0.16 (95% CI -0.19 to 0.51) (Analysis 1.1).
Outcome 3 progression AMD: dichotomous
Only the AREDS trial contributed to this outcome. People taking
antioxidant vitamins plus zinc were less likely to progress to ad-
vanced AMD. The OR adjusted for age, sex, race, AMD category
and baseline smoking status was 0.68, 95% CI 0.53 to 0.87.
Outcome 4 progression AMD: continuous
Only one trial reported the progression of AMD in a continuous
format (AMDSG), with 25 people randomised to treatment and
24 to control. There was little evidence of any effect of treatment
at 18 months (mean difference -0.06, 95% CI -0.62 to 0.50). The
power of the study was low.
Comparison 2: zinc versus placebo
Four trials have investigated the effect of zinc supplementation
(AREDS; Holz 1993 (published in abstract form only); Newsome
1988; Stur 1996). In addition there is one unpublished study for
which we have no data (France 1998).
Outcome 1, distance visual acuity: loss of three or more lines
Two trials reported visual acuity data in this format (AREDS;
Newsome 1988). The pooled analyses include a total of 984 people
randomised to zinc supplementation and 974 to placebo. The
trials were consistent I² = 0%. There was a modest beneficial effect
of treatment on visual acuity (pooled OR 0.81, 95% CI 0.66 to
0.99). (Analysis 2.1)
Outcome 2 distance visual acuity: mean
Two trials provided data for this outcome (Newsome 1988; Stur
1996). A total of 77 people were randomised to zinc supplemen-
tation and 78 to placebo in these two trials which had a maxi-
mum treatment and follow-up duration of 24 months. The re-
sults of these trials were less consistent, I2 = 56.6% (Analysis 2.2).
Newsome 1988 found that there was more visual acuity loss in
the control group than the treatment group although this did not
reach statistical significance. Stur 1996 found little difference be-
tween the two groups with respect to mean visual acuity at the end
of the study.
In Stur 1996 the primary outcome was incidence of choroidal
neovascularisation (CNV) in all patients. During the treatment
period, a CNV developed in the study eye in 14 patients (nine
in the treatment group, five in the placebo group). People who
experienced a CNV were not included in the analyses of visual
acuity.
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Outcome 3 progression AMD: dichotomous
Three trials provided data for this outcome (AREDS; Holz 1993;
Stur 1996). A total of 969 people were randomised to zinc supple-
mentation and 974 to placebo. Overall, there was a modest benefit
of treatment (Analysis 2.3). The pooled OR was 0.73 (95% CI
0.58 to 0.93). Stur 1996 had quite different results to the other
two trials. Over the treatment period, nine people experienced a
CNV in the study eye in the zinc group compared to five people in
the placebo group. This may have been a chance finding, however.
The OR for that trial (2.31) had wide confidence intervals and
the results are therefore also consistent with a protective effect of
treatment (95%CI 0.58 to 9.26). Overall, the I2 value was 29.0%.
Holz 1993 has been published in abstract form only so we have
little information about this trial.
Comparison 3: any multivitamin or single component
antioxidant supplement versus placebo
Outcome 1, distance visual acuity: loss of 15 or more letters
Three trials contributed to this analysis (AREDS;Newsome 1988;
VECAT) . The trials were reasonably consistent (I2 = 27.7%)
(Analysis 3.1). Overall there was a small beneficial effect of sup-
plementation (pooled OR fixed-effect model 0.81, 95% CI 0.67
to 0.98, P = 0.03). A random-effects model gave a different result
(pooled OR 0.83, 95% CI 0.63 to 1.09, P = 0.18). The difference
in these two models reflects the difference in weighting given to
the largest trial (AREDS) - 75% in the fixed-effect model versus
63% in the random-effects model.
Outcome 2, distance visual acuity: mean
Not all trials reported visual acuity data in a dichotomous format.
Some trials reported average distance visual acuity at the end of
the follow-up period or the mean change in visual acuity.
Five trials contributed to this analysis (AMDSG; Kaiser 1995;
Newsome 1988; Stur 1996; Veterans LAST study). A total of 146
people were randomised to treatment and 140 to control. The
results of the different studies were consistent (I2 = 0%) (Analysis
3.2). There was little evidence of any benefit of treatment. The
pooled standardised mean difference (random-effects model) was
0.02 (95% CI -0.21 to 0.26). A fixed-effect model gave identical
results. Duration of treatment and follow up in these trials ranged
from 6 to 24 months.
Outcome 3, progression AMD: dichotomous
Data on the progression of AMDwas not reported or was reported
in such a way as to make it difficult to extract data for this review
in three studies (Kaiser 1995; Newsome 1988; Veterans LAST
study).
Four trials contributed data on the progression of AMD as a di-
chotomous outcome (AREDS; Holz 1993; Stur 1996; VECAT)
(Analysis 3.3). The results of the trials were inconsistent (I2 =
64.2%) with the ORs for the individual studies ranging from 0.50
to 2.31. Estimating a pooled OR, therefore, was not of value in
this case. Moreover, these trials were quite different in terms of the
interventions studied, follow-up period and method of evaluating
progression of AMD. (See Table 1).
Outcome 4, progression AMD: continuous
One study (AMDSG) reported data on the progression of AMD
in a continuous format. There was little evidence for any benefit
of treatment (mean difference -0.06, 95% CI -0.62 to 0.50). The
number of participants in this analysis was small with 35 in the
treatment group and 24 in the control group.
There was limited information from the Chinese trial (Wang
2004), particularly about the definitions of the outcome.However,
the authors reported that supplementation with zinc, vitamin E
and vitamin C over 24 months had no effect on the progression of
early ARM (chi-squared test P > 0.05) but had a beneficial effect
on the progression of the disease in people with advanced AMD.
12/124 people receiving supplements who had large drusen, ge-
ographic atrophy or neovascularisation in one eye progressed to
“advanced AMD” (not defined but perhaps comparable to the
AREDS definitions) compared to 36/124 in the placebo group
(chi-squared P < 0.05).
Comparison 4: Vitamin E versus placebo
There has only been one trial investigating vitamin E alone (VE-
CAT). This trial randomised 587 participants to vitamin E sup-
plementation and 592 to placebo and followed them up for four
years on average.
Outcome 1 distance visual acuity: loss of three or more lines
Outcome 2 progression of AMD
There was no evidence of any effect of treatment either on visual
acuity (OR 1.05, 95% CI 0.70 to 1.57) or progression of AMD
(OR 1.11, 95% CI 0.80 to 1.55). Over 80% of participants in
this trial did not have signs of ARM or AMD.
Comparison 5: lutein or zeaxanthin versus placebo
Outcome 1 distance visual acuity: mean
There has only been one trial published to date comparing sup-
plementation with lutein versus placebo (Veterans LAST study).
The trial was small with a total of 25 people randomised to lutein
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supplementation and 27 to placebo; the treatment duration and
follow up was 12 months. The only outcome of relevance to this
review, for which data could be extracted, was mean visual acuity
at the end of the study. This showed little evidence of any effect of
treatment: mean difference logMAR acuity 0.04 (95% CI -0.15
to 0.23). The power of the study was low.
Quality of life
None of the trials have reported on quality of life.
Adverse effects
The main reported adverse effect leading to withdrawal from the
studies was gastrointestinal symptoms. Of 286 people randomised
into trials of zinc sulfate supplementation compared to placebo,
5/146 zinc-treated people withdrew due to gastrointestinal symp-
toms compared to 2/140 controls. No-one developed copper-de-
ficiency anaemia.
In AMDSG one person developed an ’allergic reaction’ although
it was not clear whether or not this was related to the treatment.
AREDS considered a number of safety outcomes. They conducted
over 100 comparisons of zinc versus no zinc and antioxidants ver-
sus no antioxidants. Participants in the antioxidant arms more
frequently reported yellow skin (8.3% versus 6.0%, P = 0.008).
Participants in the zinc arms reported more anaemia (13.2% ver-
sus 10.2%, P = 0.004), however, serum haematocrit levels were
the same. They found that participants taking zinc had a lower
mortality. Later follow-up of the cohort of people taking part in
the AREDS study found that there was a significant increase in
hospital admissions due to genitourinary diseases in people tak-
ing zinc supplements (11.1% versus 7.6% P = 0.0003) (Johnson
2007).
D I S C U S S I O N
The trials contributing to this review fall into two categories. There
are two large trials with reasonably long treatment duration and
follow up of four to six years (AREDS; VECAT). The other six
trials are smaller (ranging from 20 to 151 participants) and have
shorter duration of treatment and follow up (6 to 24 months).
The large trials provide reasonably clear answers to different ques-
tions. The AREDS trial provides evidence that long-term supple-
mentation with vitamins C, E, beta-carotene and zinc, in people
with AMD, reduced the risk of progression of the disease and vi-
sual acuity loss. The overall benefit is modest with a risk reduc-
tion in the order of 20% to 25%. However, given that treatment
options for AMD are limited, and vision loss is rarely recovered,
this is of interest to people with AMD.
The VECAT study suggests that the general population should
not take vitamin E with a view to preventing the incidence or
progression of AMD. However, the study was underpowered to
answer the question as to whether people with signs of AMD, such
as those participating in the AREDS study, should take vitamin
E. Currently VECAT is the only published trial on vitamin E
supplementation and AMD.
The other trials of multivitamin preparations, Ocuguard (
AMDSG), Ocupower (Veterans LAST study) and Visaline (Kaiser
1995) are too small to provide evidence either way. Pooling results,
where possible, did not provide evidence of any benefit of supple-
mentation. However, these trials were of relatively short duration.
A total of five trials investigated zinc supplementation (AREDS;
France 1998; Holz 1993; Newsome 1988; Stur 1996). The
AREDS study indicated that the beneficial effect of zinc supple-
mentation was of a similar order to that of vitamin supplementa-
tion. The other trials providemore conflicting evidence.Newsome
1988 found a reduction in the risk of visual acuity loss with sup-
plementation over 12 to 24months.However, Stur 1996 found no
effect of treatment. Unfortunately Stur 1996, which was planned
to recruit 500 participants, was terminated early because the re-
sults of the first 40 patients at 24 months indicated no benefit of
treatment. The other two trials of zinc supplementation are as yet
unpublished, although limited results from Holz 1993 were pub-
lished in abstract form and are included here. The trialists have
been contacted with a view to including unpublished data in fu-
ture versions of this review.
The main evidence that antioxidant vitamin and mineral supple-
mentation is of benefit comes from the AREDS trial. As AREDS
is a large well-conducted randomised study, potential biases will
have been minimised. The only area where bias may have been
introduced is if there were different systemic effects of the antioxi-
dant and zinc supplementation (for example, yellowing of skin or
difficulty swallowing tablets) which led the participants to guess
which group they were in or alternatively, the retinal fundus pho-
tographs might have been different in some way such that the
graders response was affected by treatment group. There is little
evidence that this was a problem in the study.
AREDS was the only study to examine in detail the question of
safety. They found little evidence of harm, however, recent follow-
up of the cohort suggests an increased risk of hospital admission
due to genitourinary complications in people taking the zinc sup-
plements. The safety of some of the components of the AREDS
formulation have been questioned in other studies. Two large ran-
domised controlled trials have indicated that smokers who take
beta-carotene may be at increased risk of developing lung cancer
(ATBC; Omenn 1996). The Heart Outcomes Prevention Evalu-
ation (HOPE) Study found that, among people with vascular dis-
ease or diabetes, vitamin E supplementation was associated with
a higher risk of heart failure (Hope 2005).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
People with AMDmay experience modest delay in progression of
the disease with antioxidant vitamin and mineral supplementa-
tion. This finding is drawn from one large trial conducted in a rel-
atively well-nourished American population. Until it is replicated
by other large-scale trials in other populations we will not know
whether these findings can be applied more generally.
Antioxidant vitamin andmineral supplements are readily available
for purchase without prescription in many countries. The deci-
sion as to whether to take these supplements is at the discretion
of the person with AMD. The following benefits and harms need
to be considered. People with AMD may delay the progression
of their condition if they take antioxidant vitamins and zinc at
the levels described in this review. Given that there are few other
interventions that offer much in the way of disease prevention or
cure this is an important consideration. However, harmful effects
associated with long-term vitamin supplementation, particularly
in smokers and people with vascular disease, cannot be ruled out.
A healthy diet with a variety of fresh fruit and vegetables will have
many benefits and is unlikely to be harmful. It may be difficult,
however, to consume as part of a normal diet the levels of an-
tioxidants and zinc described in the trials included in this review
. For example, one orange provides 80 mg of vitamin C; this is
a relatively high amount. However, one would need to eat six to
seven oranges daily to obtain 500 mg vitamin C.
There is currently considerable interest in the potential role of
lutein and zeaxanthin supplementation in AMD. This review in-
cludes only one small equivocal trial on lutein. Such supplements
currently cannot be recommended.
Implications for research
Trials in other populations, preferably with a variety of nutritional
status, are required. These trials should have a large enough sample
size to demonstrate effects that are meaningful for people and
should also include a component on quality of life. It is likely that
AMDdevelops overmany years. Three categories of peoplemay be
identified: healthy people at risk because of age or genetic factors;
people with early stages of the disease; people with intermediate or
late-stage disease. There are likely to be differences in the potential
protective effect of antioxidant supplementation depending on the
stage of the disease.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AMDSG
Methods Method of allocation: Sponsor prepared coded tablets.
Masking: Participant - not clear; Provider - yes; Outcome - yes.
Losses to follow up: 4 died (2 treatment, 2 control); 1 adverse effect withdrawn (treatment); 7 lost to
follow up (1 treatment, 6 control)
Participants Country: USA.
Number of participants randomised: 71 veterans.
Age: Average age 72 years.
Sex: 66 male 5 female.
Inclusion criteria: People with a monocular one line drop in Snellen visual acuity not attributable to
cataract, amblyopia, systemic or ophthalmic disease AND clinically observable drusen, RPE disruption
and loss of macular reflex.
Exclusion criteria: Greater than one year use of vitamins; ex-prisoners of war, chronic alcoholics with
tobacco/nutritional amblyopia or gastrointestinal absorption disorders
Interventions Treatment: Ocuguard (Twin Lab Inc, Ronkonkoma, NY) broad spectrum antioxidant: beta carotene
20,000 IU, vitamin E 200 IU, vitamin C 750 mg, citrus bioflavonoid complex 125 mg, quercitin
(bioflavonoid) 50 mg, bilberry extract (bioflavonoid) 5 mg, rutin (bioflavonoid) 50 mg, zinc picolinate
12.5 mg, selenium 50 mcg, taurine 100 mg, n-acetyl cysteine 100mg, l-glutathione 5 mg, vitamin B2 25
mg, chromium 100 mcg.
Control: Starch placebo.
Duration: 18 months.
Outcomes Snellen acuity with best refraction converted to logMAR units for analysis; Near vision M units with dual
sided Bailey-Lovie chart; Contrast sensitivity; Retinal grading score (adapted fromChesapeake Bay Study)
; Subjective perception of vision; Adverse gastrointestinal reactions
Notes Treatment and placebo may not have been identical.
Funders: Twin Laboratories Inc, Ronkokoma NY; StereoOptical Inc, Chicago, IL.; Eye Communications
Inc, Upland, CA; Illinois College of Optometry, Chicago, IL; Pacific University College of Optometry,
Forest Grove, OR; Ezell Foundation, American Academy of Optometry, Rockville, MD
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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AREDS
Methods Method of allocation: Coded bottles.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow-up: 2.4% balanced across study groups.
Participants Country: USA.
Number of participants randomised: 3640.
Age: Average age 69 years (range 55 to 80).
Sex: 56% female.
Inclusion criteria: 20/32 or better in at least one eye; ocular media clear and therefore able to obtain
adequate stereoscopic fundus photographs; at least one eye free from eye disease that could complicate
assessment of AMD.
Exclusion criteria: Illness or disorders that would make long term follow-up or compliance with study
protocol unlikely or difficult
Interventions Treatment: Antioxidants (500mg vitamin C, 400IU vitamin E, 15mg beta carotene) zinc (80mg of zinc
as zinc oxide and 2mg of copper as cupric oxide).
Control: Placebo identical in external appearance and similar in internal appearance and taste.
Duration: 7 years.
Outcomes Primary outcomes: (1) progression to advanced AMD and (2) 15 letter or more decrease in visual acuity
score. AMD assessed using stereoscopic fundus colour photograph; visual acuity measured using EDTRS
logMAR chart. Safety outcomes included: reported adverse events; serum levels of haemoglobin; hospi-
talisations and mortality
Notes 2x2 factorial design. 67% participants took additional supplements to RDA levels (Centrum). In 1996
current smokers offered option of discontinuing supplementation; 2% of participants and 18% of smokers
did so. A further 2.3% reassigned to no beta-carotene group. Intention to treat analysis maintained
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Holz 1993
Methods Method of allocation: Not known.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow-up: Not known.
Participants Country: UK.
Number of participants randomised: 58.
Age: 55 - 82, mean 68.
Interventions Treatment: 100mg zinc sulfate twice daily.
Control: Placebo.
Duration: 12 to 24 months.
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Holz 1993 (Continued)
Outcomes Visual acuity; Contrast sensitivity; Dark adaptation; Stereo fundus photographs and fluorescein an-
giograms
Notes Data available from abstract only.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kaiser 1995
Methods Method of allocation: Sponsor prepared coded tablets.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow-up: None.
Participants Country: Switzerland.
Number of participants randomised: 20.
Age: over 50. Average age 72 in treatment group, 74 in control group.
Sex: 7 male, 20 female.
Inclusion criteria: People with nonserous AMD. All participants had regional atrophy of the pigment
epithelium.
Corrected visual acuity was between 20/100 and 20/25 with distance correction of less than four dioptres.
Exclusion criteria: People with diabetes mellitus, endocrine problems, cardiac dysrhythmia, cardial infarc-
tion or hypotension, other ocular disorders
Interventions Treatment: Visaline (Novopharma Cham, Switzerland). Each tablet contains 1.5mg buphenine HCl, 10
mg beta-carotene, 10 mg tocopherol acetate, and 50 mg ascorbic acid. Participants took 2 tablets in the
morning and at night, daily except for Saturdays and Sundays.
Control: Placebo resembling active treatment prepared by sponsor.
Duration: 6 months.
Outcomes Only one eye per person was evaluated. In cases of bilateral AMD, the eye with better visual acuity was
selected.
Distance and near visual acuity; Intraocular pressure; Visual fields; Lens opacity; Retinal visual acuity;
Colour vision; Contrast sensitivity
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Newsome 1988
Methods Method of allocation: Computer generated table of random numbers.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow up: 23 (10 treatment, 13 placebo).
Participants Country: USA.
Number of participants randomised: 174.
Age: 42 to 89.
Sex: 61 men 113 women.
Inclusion criteria: Macular degeneration: clinically visible drusen with varying degrees of pigmentary
change with visual acuity in one eye of 20/80 or better.
Exclusion criteria: Cataract reducing vision more than one line; other known serious eye disease; diabetes
mellitus; other known systematic/metabolic disease or congenital condition which might interfere with
results
Interventions Treatment: Zinc sulfate 100mg twice daily.
Control: Identical tablets with lactose and fructose.
Duration: 1 to 2 years.
Outcomes Pinhole corrected visual acuity using ETDRS charts; Changes in visible pigment, drusen or atrophy from
grading of macular photographs; Adverse effects of zinc including copper deficiency anaemia
Notes Funders: Research Fund, Department of Veterinary Science, Utah State University, Logan; James L Shupe,
DVM; Mary Katherine Peterson Foundation, Houston
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Stur 1996
Methods Method of allocation: sponsor prepared coded bottles.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow-up: 6 withdrawn due to adverse gastrointestinal effects (4 treatment, 2 control); 14
withdrawn when developed neovascularisation (9 treatment, 5 control); 14 lost to follow up (6 treatment,
8 control)
Participants Country: Austria.
Number of participants randomised: 112.
Age: 50 plus.
Sex: 48 men, 64 women.
Inclusion criteria: Exudative AMD in one eye (defined as angiographic evidence of classic or occult
choroidal neovascularisation or RPE detachment) and early ARM with visual acuity 20/40 or better in
other eye (early ARM: macular drusen with no angiographic evidence of exudative lesion).
Exclusion criteria: Dense senile cataract; any other eye disease which could produce significant and per-
manent loss of visual acuity during follow up; physical status that could prevent follow up; history of
serious systemic or metabolic disease
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Stur 1996 (Continued)
Interventions Treatment: Zinc sulfate 200 mg once daily. Lemon flavoured effervescent tablet made of citric acid
containing saccharine and sorbitol.
Control: As treatment but without zinc sulfate.
Duration: 24 months.
Outcomes Best corrected LogMAR visual acuity measured using Bailey-Lovie chart; Contrast sensitivity; Incidence
of choroidal neovascularisation; Progression of disease (Wisconsin Age-related Maculopathy Grading
System); Copper deficiency anaemia
Notes A priori sample size estimate was 500 patients but trial stopped early because interim analysis showed no
detectable trend.
Funders: Astra, Linz, Austria; Austrian Foundation for the Propagation of Scientific Research
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
VECAT
Methods Method of allocation: Coded bottles.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow up: Not known.
Participants Country: Australia.
Number of participants randomised: 1204.
Age: 55 - 80 mean 66.
Sex: 56% female.
Inclusion criteria: Lens and retina of at least one eye available for documentation.
Exclusion criteria: Previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation
use; serious disease; regular use or sensitivity to vitamin E
Interventions Vitamin E 500 IU per day: natural vitamin E in soybean oil medium.
Control: Placebo identical in sight, taste and smell.
Duration: 4 years.
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs graded using
International Grading Scheme
Notes Worse eye used as the study eye.
Methodology published but results available from abstract only
Risk of bias
Item Authors’ judgement Description
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VECAT (Continued)
Allocation concealment? Yes A - Adequate
Veterans LAST study
Methods Method of allocation: Coded bottles.
Masking: Participant - yes; Provider - yes; Outcome - yes.
Losses to follow up: 7 withdrew, 4 lost to follow-up, 3 died. Slightly lower % follow up in group 2 (lutein/
antioxidant) 80% compared to other 2 group (lutein alone 86% placebo 87%)
Participants Country: USA.
Number of participants randomised: 90.
Approximate average age 75 years.
Sex: 86/90 male.
Inclusion criteria: Atrophic AMD diagnosed by ophthalmoscopy and at least one visual abnormality:
reduced contrast sensitivity, photo-stress glare recovery deficit or deficit on Amsler grid. Clear ocular
media, free of any other ocular/systemic disease that could affect central or parafoveal macular visual
function.
Exclusion criteria: Cataract or retinal surgery within 6 months, photosensitizing drugs, taken lutein
supplements within the previous six months
Interventions Treatment: Group 1 L: Lutein 10mg non-esterified lutein (FloraGlo from Kemin Foods International,
Des Moines, Iowa); Group 2 L/A: Lutein plus additional antioxidants and nutrients (OcuPower (see
below) from Nutraceutical Sciences Institute (NSI), Boynton Beach, Florida) Group 3 P: maltodextrin.
Duration: 12 months
Ocupower had a range of nutrients including lutein , vitamin A, betacarotene, vitamins C, D3, E, B1,
B2, B3, B5, B6, B12, folic acid, biotin, calcium, magnesium, iodine, zinc copper, manganese, selenium,
chromium, molybdenum, lycopene, bilberry extract, alpha lipoic acid, N-acetyl cysteine, quercetin, rutin,
citrus bioflavonoids, plant enzymes, black pepper extract, malic acid, taurine, L-glycine, L-glutathione,
boron
Outcomes The following clinical measurements were made: Lens opacity; retinal images; Macular Pigment Optical
Density (MPOD); visual acuity (Snellen) distance and near; glare testing; glare recovery; contrast sensitiv-
ity; VFQ-14 (activities of daily living, night driving, glare recovery symptoms) ; Amsler grid; self-reported
vision
Notes It was difficult to extract data on outcomes of relevance to this review: i.e. visual acuity and progression
of AMD
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Wang 2004
Methods Method of allocation: Unknown.
Masking: Participant - unknown; Provider - unknown; Outcome - unknown.
Losses to follow up: unknown
Participants Country: China
Number of participants randomised: 400
188 men / 212 women aged 52 to 76, average age 65
Interventions Treatment: zinc oxide 80mg daily, vitamin C, vitamin E. Control: placebo
Duration 24 to 32 months.
Outcomes Outcomes: visual acuity
Notes Limited information available on this trial. AMD patients were stratified in early and late stage disease
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
AMD: age-related macular degeneration
ETDRS: Early Treatment Diabetic Retinopathy Study
RPE: retinal pigment epithelium
MPOD: macular pigment optical density
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bahrami 2006 Not AMD.
Barakat 2006 Not antioxidant vitamin.
Benzie 2006 Bioavailability study
Bone 2007 Bioavailability study.
Cangemi 2007 No control group.
Christen 2007 RCT in healthy population group. Included in Cochrane review on prevention of AMD with antioxidant
supplements
Cumurcu 2006 Not RCT.
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(Continued)
Franciose 2006 Bioavailability study.
Goodrow 2006 Bioavailability study.
Kamburoglu 2006 Not RCT, not antioxidant
Khachik 2006 Bioavailability study.
Kopsell 2006 Bioavailability study.
Lim 2006 Not antioxidant
LUNA study Bioavailability study.
LUXEA MPOD only measured; no clinical outcomes.
Moeller 2006 Not RCT.
Nolan 2006 Not RCT.
Nolan 2007 Not RCT.
Nussenblatt 2006 Not AMD.
Owsley 2006 Not antioxidant.
Rosenthal 2006 Small dose ranging study. Data on vision only collected for nine months and not possible to extract from report
Vannas 1958 Allocation concealment inadequate.
Wang 2007 Bioavailability study.
Wenzel 2006 Bioavailability study.
Zhao 2006 Bioavailability study.
AMD: age-related macular degeneration
MPOD: macular pigment optical density
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Multivitamin supplement versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: mean 3 131 Std. Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.19, 0.51]
1.1 Mean visual acuity at end
of study
3 131 Std. Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.19, 0.51]
Comparison 2. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: loss of 3
or more lines
2 1958 Odds ratio (Fixed, 95% CI) 0.81 [0.66, 0.99]
2 Distance visual acuity: mean 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Mean visual acuity at end
of study
1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 Change in visual acuity 1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Progression AMD: dichotomous 3 1943 Odds ratio (Fixed, 95% CI) 0.73 [0.58, 0.93]
Comparison 3. Any multivitamin or single component antioxidant supplement versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: loss of 3
or more lines
3 4970 Odds ratio (Fixed, 95% CI) 0.81 [0.67, 0.98]
2 Distance visual acuity: mean 5 286 Std. Mean Difference (IV, Random, 95% CI) 0.02 [-0.21, 0.26]
2.1 Mean visual acuity at end
of study
3 157 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.21, 0.42]
2.2 Change in visual acuity 2 129 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.66, 0.59]
3 Progression AMD: dichotomous 4 Odds ratio (Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Multivitamin supplement versus placebo, Outcome 1 Distance visual acuity:
mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Multivitamin supplement versus placebo
Outcome: 1 Distance visual acuity: mean
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
AMDSG 35 0.33 (0.41) 24 0.29 (0.24) 44.4 % 0.11 [ -0.41, 0.63 ]
Kaiser 1995 9 0.17 (0.7) 11 0.22 (0.66) 15.5 % -0.07 [ -0.95, 0.81 ]
Veterans LAST study 25 -0.03 (0.242347) 27 -0.14 (0.437431) 40.1 % 0.30 [ -0.24, 0.85 ]
Total (95% CI) 69 62 100.0 % 0.16 [ -0.19, 0.51 ]
Heterogeneity: Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours treatment Favours control
Analysis 2.1. Comparison 2 Zinc versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 1 Distance visual acuity: loss of 3 or more lines
Study or subgroup Zinc Placebo log [Odds ratio] Odds ratio Weight Odds ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 904 903 -0.1985 (0.1045) 97.2 % 0.82 [ 0.67, 1.01 ]
Newsome 1988 80 71 -0.8159 (0.6123) 2.8 % 0.44 [ 0.13, 1.47 ]
Total (95% CI) 100.0 % 0.81 [ 0.66, 0.99 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 2.2. Comparison 2 Zinc versus placebo, Outcome 2 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 2 Distance visual acuity: mean
Study or subgroup Zinc Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
Stur 1996 37 0.05 (0.12) 41 0.03 (0.14) 0.15 [ -0.29, 0.60 ]
2 Change in visual acuity
Newsome 1988 40 0.08 (0.12) 37 0.14 (0.22) -0.34 [ -0.79, 0.11 ]
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 2.3. Comparison 2 Zinc versus placebo, Outcome 3 Progression AMD: dichotomous.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 3 Progression AMD: dichotomous
Study or subgroup Zinc Placebo log [Odds ratio] Odds ratio Weight Odds ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 904 903 -0.3425 (0.1266) 95.8 % 0.71 [ 0.55, 0.91 ]
Holz 1993 28 30 -0.6931 (1.1533) 1.2 % 0.50 [ 0.05, 4.79 ]
Stur 1996 37 41 0.8391 (0.7073) 3.1 % 2.31 [ 0.58, 9.26 ]
Total (95% CI) 100.0 % 0.73 [ 0.58, 0.93 ]
Heterogeneity: Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
Analysis 3.1. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 1 Distance visual acuity: loss of 3 or more lines.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 1 Distance visual acuity: loss of 3 or more lines
Study or subgroup Antioxidant Placebo log [Odds ratio] Odds ratio Weight Odds ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2737 903 -0.2614 (0.1113) 75.4 % 0.77 [ 0.62, 0.96 ]
Newsome 1988 80 71 -0.8159 (0.6123) 2.5 % 0.44 [ 0.13, 1.47 ]
VECAT 587 592 0.0477 (0.2053) 22.1 % 1.05 [ 0.70, 1.57 ]
Total (95% CI) 100.0 % 0.81 [ 0.67, 0.98 ]
Heterogeneity: Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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Analysis 3.2. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 2 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 2 Distance visual acuity: mean
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean visual acuity at end of study
AMDSG 35 0.33 (0.41) 24 0.29 (0.24) 20.2 % 0.11 [ -0.41, 0.63 ]
Kaiser 1995 9 0.17 (0.7) 11 0.22 (0.66) 7.0 % -0.07 [ -0.95, 0.81 ]
Stur 1996 37 0.05 (0.12) 41 0.03 (0.14) 27.6 % 0.15 [ -0.29, 0.60 ]
Subtotal (95% CI) 81 76 54.8 % 0.11 [ -0.21, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Change in visual acuity
Newsome 1988 40 0.08 (0.12) 37 0.14 (0.22) 26.9 % -0.34 [ -0.79, 0.11 ]
Veterans LAST study 25 -0.03 (0.25) 27 -0.14 (0.44) 18.2 % 0.30 [ -0.25, 0.85 ]
Subtotal (95% CI) 65 64 45.2 % -0.04 [ -0.66, 0.59 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.12, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 146 140 100.0 % 0.02 [ -0.21, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.94, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 3.3. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 3 Progression AMD: dichotomous.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 3 Progression AMD: dichotomous
Study or subgroup Antioxidant Placebo log [Odds ratio] Odds ratio Odds ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
AREDS 2737 903 -0.3857 (0.1242) 0.68 [ 0.53, 0.87 ]
Holz 1993 28 30 -0.6931 (1.1533) 0.50 [ 0.05, 4.79 ]
Stur 1996 37 41 0.8391 (0.7073) 2.31 [ 0.58, 9.26 ]
VECAT 587 592 0.1033 (0.1696) 1.11 [ 0.80, 1.55 ]
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
A D D I T I O N A L T A B L E S
Table 1. Supplementary information on trials
Study Type of AMD Treatment Treatment
duration
Follow up Visual acuity Progression
AMD
Notes
AMDSG Early ARM Ocuguard 18 months 18 months Snellen con-
verted to log-
MAR: contin-
uous score
Based on
Chesapeake
Bay grading
but using indi-
rect ophthal-
moscopy: ex-
pressed as an
average grade
AREDS ARM & VA
20/32 or bet-
ter in one eye.
956/3640 had
AMD.
Vitamin C, E,
beta-carotene,
zinc. Factorial
design
Average dura-
tion 6.3 years
Aver-
age follow-up
6.3 years, 2.
4% lost to fol-
low up
Loss of 3 or
more lines VA
(equivalent to
doubling
visual angle)
Progression to
advanced
AMD: photo-
coagulation or
other
treatment for
CNV; GA in-
volving center
of the macula,
27Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Supplementary information on trials (Continued)
RPE detach-
ment, hemor-
rhage un-
der the retina,
subretinal fi-
bro-
sis. Color fun-
dus photogra-
phy
Holz 1993 People with
drusen
Zinc Not stated but
as-
sume same as
follow-up du-
ration
12-24 Not reported “Incidence of
new exudative
or dry macula
lesions”
Kaiser 1995 “Nonserous
AMD”
Visaline 6 6 Average
Snellen score
reported, con-
verted to log-
MAR for this
review
Not reported
Newsome
1988
Drusen and/
or pigmentary
change, VA
20/80 or bet-
ter
Zinc 12-24 12-24 Number of
letters lost on
logMAR
chart, con-
verted to log-
MAR score for
this review
Difficult to ex-
tract data on
this. Reported
number with
increased pig-
ment,
drusen and at-
rophy for two
observers. In
general found
results favour-
ing the zinc
treated group
Stur 1996 Neovascular
AMD in one
eye, VA better
than 20/40 in
other eye
Zinc 24 24 Mean
logMAR score
NOTE:
patients with
neo-
vascular event
excluded from
this outcome
Incidence
of neovascular
lesion in study
eye
Original trial
of n = 500 ter-
minated ?by
spon-
sor (Astra) be-
cause statisti-
cal evaluation
of first 40 pa-
tients at 24
months follow
up
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Table 1. Supplementary information on trials (Continued)
“did not show
any treatment
benefit”
VECAT Early
AMD (18%)
Late AMD (0.
5%). Rest pre-
sumably
had no signs of
ARM
Vitamin E 48 48 Loss of more
than 9 letters
on
logMAR chart
(two lines)
In-
vestigators de-
fined six stages
of AMD pro-
gres-
sion and de-
fined progres-
sion as move-
ment from a
lower stage to
a higher stage
in their worst
eye
Veterans Last
study
Atrophic
AMD and re-
duced vision
Lutein and/or
Ocupower
12 12 Change in log-
MAR score
Data not re-
ported
A P P E N D I C E S
Appendix 1. CENTRAL and NRR search strategies for Issue 3, 2007
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
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#20 MeSH descriptor alpha-Tocopherol
#21 alpha tocopherol*
#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
Appendix 2. MEDLINE search strategy used on OVID up to August 2007
1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol$.tw.
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27. exp beta carotene/
28. caroten$.tw.
29. exp ascorbic acid/
30. ascorbic acid$.tw.
31. vitamin C.tw.
32. exp Vitamin E/
33. exp alpha tocopherol/
34. alpha?tocopherol$.tw.
35. alpha tocopherol$.tw.
36. vitamin E.tw.
37. exp Vitamin B12/
38. vitamin B12.tw.
39. cobalamin$.tw.
40. exp antioxidants/
41. ((antioxidant$ or anti) adj1 oxidant$).tw.
42. exp carotenoids/
43. carotenoid$.tw.
44. exp zinc/
45. zinc$.tw.
46. exp riboflavin/
47. riboflavin$.tw.
48. exp selenium/
49. selenium$.tw.
50. exp lutein/
51. lutein$.tw.
52. exp xanthophylls/
53. xanthophyll.tw.
54. zeaxanthin$.tw.
55. or/23-54
56. 22 and 55
57. 12 and 56
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE search strategy used on OVID up to August 2007
We used the following strategy to search EMBASE on OVID to August 2007.
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
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17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. or/33-41
43. exp vitamins/
44. exp Retinol/
45. vitamin A.tw.
46. retinol$.tw.
47. exp beta carotene/
48. caroten$.tw.
49. exp ascorbic acid/
50. ascorbic acid$.tw.
51. vitamin C.tw.
52. exp alpha tocopherol/
53. alpha?tocopherol$.tw.
54. alpha tocopherol$.tw.
55. vitamin E.tw.
56. vitamin B12.tw.
57. exp cyanocobalamin/
58. cobalamin$.tw.
59. exp antioxidants/
60. ((antioxidant$ or anti) adj1 oxidant$).tw.
61. exp carotenoid/
62. exp zinc/
63. zinc$.tw.
64. exp riboflavin/
65. riboflavin$.tw.
66. exp selenium/
67. selenium$.tw.
68. exp zeaxanthin/
69. zeaxanthin$.tw.
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70. lutein$.tw.
71. xanthophyll.tw.
72. or/43-71
73. 42 and 72
Appendix 4. PubMed search strategy used on 24 January 2006 (last 60 days)
The following strategy was used to search PubMed .
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
Appendix 5. AMED search strategy used up to January 2006
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
Appendix 6. SIGLE search strategy used up to March 2005
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
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WH A T ’ S N E W
Last assessed as up-to-date: 1 August 2007.
Date Event Description
28 August 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 1, 1998
Date Event Description
12 August 2007 New search has been performed Issue 1 2008: Results of trial from China (Wang et al)
added. Report from AREDS study on risk of hospital
admission due to genitourinary complications in people
taking high dose zinc.
Graphs with only one trial have been deleted and results
have been reported in the text
19 January 2006 New citation required and conclusions have changed Substantive amendment
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• Moorfields Eye Hospital NHS Trust, UK.
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External sources
• Guide Dogs for the Blind Association, UK.
N O T E S
The Cochrane Eyes and Vision Group editorial team is aware that there has been some criticism of one trial included in this review
(AREDS). We welcome comments and criticisms on the review through the feedback system of The Cochrane Library.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements; Antioxidants [∗therapeutic use]; Macular Degeneration [∗prevention & control]; Minerals [∗therapeutic use];
Randomized Controlled Trials as Topic; Vitamins [∗therapeutic use]
MeSH check words
Aged; Humans
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